These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12694528)

  • 21. Continuous infusion of factor IX concentrate to induce immune tolerance in two patients with haemophilia B.
    Tengborn L; Berntorp E
    Haemophilia; 1998 Jan; 4(1):56-9. PubMed ID: 9873867
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence of factor IX inhibitor development in severe haemophilia B patients treated with only one brand of high purity plasma derived factor IX concentrate.
    Parquet A; Laurian Y; Rothschild C; Navarro R; Guérois C; Gay V; Durin A; Peynet J; Sultan Y
    Thromb Haemost; 1999 Oct; 82(4):1247-9. PubMed ID: 10544907
    [TBL] [Abstract][Full Text] [Related]  

  • 23. rFIXFc for Immune Tolerance Induction in a Severe Hemophilia B Patient with an Inhibitor and Prior History of ITI Related Nephrotic Syndrome.
    Malec L; Abshire T; Jobe S; White G
    Haemophilia; 2018 Jul; 24(4):e294-e296. PubMed ID: 30024646
    [No Abstract]   [Full Text] [Related]  

  • 24. Immune tolerance: critical issues of factor dose, purity and treatment complications.
    DiMichele DM
    Haemophilia; 2006 Dec; 12 Suppl 6():81-5; discussion 85-6. PubMed ID: 17123399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anaphylactoid reactions and nephrotic syndrome--a considerable risk during factor IX treatment in patients with haemophilia B and inhibitors: a report on the outcome in two brothers.
    Tengborn L; Hansson S; Fasth A; Lübeck PO; Berg A; Ljung R
    Haemophilia; 1998 Nov; 4(6):854-9. PubMed ID: 10028310
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.
    Astermark J; Morado M; Rocino A; van den Berg HM; von Depka M; Gringeri A; Mantovani L; Garrido RP; Schiavoni M; Villar A; Windyga J;
    Haemophilia; 2006 Jul; 12(4):363-71. PubMed ID: 16834735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of haemophilia B patients with inhibitors and anaphylaxis.
    Warrier I
    Haemophilia; 1998 Jul; 4(4):574-6. PubMed ID: 9873797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibitors in haemophilia B: the Italian experience.
    Castaman G; Bonetti E; Messina M; Morfini M; Rocino A; Scaraggi FA; Tagariello G;
    Haemophilia; 2013 Sep; 19(5):686-90. PubMed ID: 23601006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of immune tolerance using rituximab in a child with severe haemophilia B with inhibitors and anaphylaxis to factor IX.
    Barnes C; Davis A; Furmedge J; Egan B; Donnan L; Monagle P
    Haemophilia; 2010 Sep; 16(5):840-1. PubMed ID: 20546030
    [No Abstract]   [Full Text] [Related]  

  • 30. Factor IX inhibitors in haemophilia B: A report of National Haemophilia Registry in China.
    Dou X; Zhang W; Poon MC; Zhang X; Wu R; Feng X; Yang L; Cheng P; Chen S; Wang Y; Zhou H; Huang M; Song Y; Jin C; Zhang D; Chen L; Liu W; Zhang L; Xue F; Yang R
    Haemophilia; 2023 Jan; 29(1):123-134. PubMed ID: 36163649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Switching haemophilia products and inhibitor risk: a United States' perspective.
    Nance D; Rodgers GM
    Eur J Haematol; 2015 Apr; 94(4):283. PubMed ID: 25800968
    [No Abstract]   [Full Text] [Related]  

  • 32. The use of rituximab as an adjuvant for immune tolerance therapy in a hemophilia B boy with inhibitor and anaphylaxis to factor IX concentrate.
    Chuansumrit A; Moonsup Y; Sirachainan N; Benjaponpitak S; Suebsangad A; Wongwerawattanakoon P
    Blood Coagul Fibrinolysis; 2008 Apr; 19(3):208-11. PubMed ID: 18388500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of an occult inhibitor to factor IX in a haemophilia B patient.
    Miller CH; Orstavik KH; Hilgartner MW
    Br J Haematol; 1985 Oct; 61(2):329-38. PubMed ID: 4041376
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suppression of secondary antibody response by intravenous immunoglobulin and development of tolerance in a patient with haemophilia B and antibodies.
    Nilsson IM; Sundqvist SB
    Scand J Haematol Suppl; 1984; 40():203-6. PubMed ID: 6591389
    [No Abstract]   [Full Text] [Related]  

  • 35. Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III study.
    Windyga J; Lissitchkov T; Stasyshyn O; Mamonov V; Ghandehari H; Chapman M; Fritsch S; Wong WY; Pavlova BG; Abbuehl BE
    Haemophilia; 2014 Sep; 20(5):651-8. PubMed ID: 24697870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prophylaxis Using a Mixture of Plasma-Derived Activated Factor VII and Factor X (pdFVIIa/FX) in a Patient with Hemophilia B Complicated by Inhibitors and Allergy to Factor IX Concentrates: A Case Report.
    Uchida E; Komori K; Kurata T; Taki M; Sakashita K
    Acta Haematol; 2021; 144(3):293-296. PubMed ID: 32702700
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rituximab for adolescents with haemophilia and high titre inhibitors.
    Fox RA; Neufeld EJ; Bennett CM
    Haemophilia; 2006 May; 12(3):218-22. PubMed ID: 16643204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The maintenance of tolerance after successful immune tolerance induction in hemophilia A and B: the North American Registry. Factor VIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis.
    DiMichele D; Kroner B;
    Haematologica; 2000 Oct; 85(10 Suppl):40-2; discussion 42-4. PubMed ID: 11187869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX.
    Nilsson IM; Berntorp E
    Prog Clin Biol Res; 1990; 324():69-78. PubMed ID: 2106694
    [No Abstract]   [Full Text] [Related]  

  • 40. Low cost industrial production of coagulation factor IX bioencapsulated in lettuce cells for oral tolerance induction in hemophilia B.
    Su J; Zhu L; Sherman A; Wang X; Lin S; Kamesh A; Norikane JH; Streatfield SJ; Herzog RW; Daniell H
    Biomaterials; 2015 Nov; 70():84-93. PubMed ID: 26302233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.